Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 67

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 67
---
,
(c) unsupervised machine learning, and (d) streamlined data ingestion and visualization makes bfLEAP™ one of the most flexible
and powerful new platforms available on the market.

The
Company will continue to evolve and improve bfLEAP™.

Bullfrog
Data Networks™

The
Company’s Bullfrog Data Networks™ solution incorporates publicly available, proprietary, and custom data sources to generate
novel insights toward target identification and validation, understanding mechanism of action, clinical trial optimization, drug repurposing,
and more. Bullfrog Data Networks™ can be created for any therapeutic area, and we use this technology in our own research and development
pipeline including in oncology and central nervous system indications. Our approach finds patient subgroups with similar molecular signatures
and identifies the most relevant genes driving disease biology. Data networks created from this process generate insights that allow
researchers to accelerate drug discovery and development and increase the odds of technical and regulatory success. In February 2025,
we entered into a collaboration agreement with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase III oncology company focused
on novel chemotherapeutic treatments for rare cancers, where we will apply our proprietary Bullfrog Data Networks™ solution, powered
by the bfLEAP® platform, and we plan to offer this solution to other biotechnology and pharmaceutical companies going forward.

 8 

Lieber
Institute for Brain Development 

On
September 8, 2023, the Company entered a data use and technology partnership agreement (the “Partnership Agreement”) with
the Lieber Institute for Brain Development (“LIBD”). The Partnership Agreement covers the right of the Company to leverage
its bfLEAP™ platform to mine LIBD’s comprehensive brain data, including transcriptomic, genomic, DNA methylation, cell-line,
clinical, and imaging data to identify previously unrecognized relationships. The goal of the partnership is to identify previously unrecognized
relationships between genes and pathways in the brain and the development of neurologic and psychiatric disorders, thereby facilitating
the development of more effective treatments for diseases of the human brain. The collaboration will proceed in two stages, with the
first involving unsupervised construction of graphical models to reveal relationships between brain diseases and genomic/biologic attributes,
with the goal of identifying new biomarkers and drug targets across disorders. The second stage will involve creating disease-specific
models that will enable identification of genes and pathways within these respective disorders. The Partnership Agreement had a one-year
term of data exclusivity to complete the